UPBHealthcare · BiotechnologyThe 9 Wall Street analysts covering Upstream Bio, Inc. hold a median 12-month price target of $31 — +362.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Upstream Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (73): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (23): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on UPB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +362.8% from it.
Of the 15 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2026 | JP Morgan | Maintains | Neutral | $8.00 → $9.00 |
| 12 Aug 2026 | Truist Securities | Maintains | Buy | $43 → $25 |
| 12 June 2026 | JP Morgan | Downgrade | Neutral | $35 → $8.00 |
| 12 June 2026 | JP Morgan | Downgrade | Neutral | — |
| 3 June 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 14 May 2026 | Mizuho | Maintains | Outperform | — |
| 27 Mar 2026 | Evercore ISI Group | Downgrade | In-Line | — |
| 18 Dec 2025 | Mizuho | Initiates | Outperform | — |
| 2 Dec 2025 | LifeSci Capital | Initiates | Outperform | — |
| 18 Nov 2025 | Evercore ISI Group | Initiates | Outperform | — |
| 14 Oct 2025 | Truist Securities | Initiates | Buy | — |
| 5 Nov 2024 | JP Morgan | Initiates | Overweight | — |
| 5 Nov 2024 | Piper Sandler | Initiates | Overweight | — |
| 5 Nov 2024 | TD Cowen | Initiates | Buy | — |
| 5 Nov 2024 | William Blair | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. UPB appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 4% of US stocks
Cheaper than 66% of US stocks
Cheaper than 65% of US stocks
Higher than 12% of US stocks
Higher than 82% of US stocks
Higher than 3% of US stocks
Higher than 30% of US stocks
Higher than 22% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Upstream Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Upstream Bio, Inc. (UPB) reported a Q2 loss of $0.73 per share, narrower than the Zacks Consensus Estimate of a $0.78 loss, and slightly improved from the $0.74 per share loss reported a year ago.
Why it matters — The smaller-than-expected quarterly loss may signal better-than-anticipated cost management or operational progress for UPB.
The 9 Wall Street analysts covering Upstream Bio, Inc. have a median 12-month price target of $31, with estimates ranging from $9 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Upstream Bio, Inc., 7 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Upstream Bio, Inc. 31 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Upstream Bio, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (73 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +362.8% from the last close, and Ticker Nerd's factor model ranks Upstream Bio, Inc. 31 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Upstream Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for UPB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $75 over the next 12 months.
Upstream Bio, Inc. returned -62.6% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Upstream Bio Inc. operates within the biotechnology sector, focusing on the development of innovative therapeutic solutions for advanced immunological diseases.
The most recent item we track (Zacks Investment Research, 11 Aug 2026): "Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates". Upstream Bio, Inc. (UPB) reported a Q2 loss of $0.73 per share, narrower than the Zacks Consensus Estimate of a $0.78 loss, and slightly improved from the $0.74 per share loss reported a year ago.
Upstream Bio Inc. operates within the biotechnology sector, focusing on the development of innovative therapeutic solutions for advanced immunological diseases. The company aims to address unmet medical needs by leveraging cutting-edge scientific research and technology advancements. Upstream Bio Inc. emphasizes the discovery and development of novel biological therapies with the potential to significantly improve patient outcomes in conditions that currently have limited or ineffective treatments. As a player in the biopharmaceutical industry, Upstream Bio collaborates with scientific institutions and industry experts to accelerate the translation of early-stage research into clinically viable products. This focus on therapeutic innovation positions Upstream Bio Inc. as a noteworthy entity in the biotechnology space, contributing to the development of treatments that could have profound impacts on patient care and the broader healthcare landscape. With its commitment to advancing medicine and improving quality of life for individuals with complex immunological disorders, Upstream Bio Inc. holds a critical role in the ongoing evolution of the biopharmaceutical market.
CEO Dr. E. Rand Sutherland M.D., M.P.H. · 75 employees · United States · https://upstreambio.com